Novartis Forecast, price target & analysts
Novartis Target price 2024 - Analyst rating & recommendation
Novartis Classifications & Recommendation:
Novartis Price Target
| Target Price | CHF102.52 |
| Price | CHF88.06 |
| Potential | 16.41% |
| Number of Estimates | 20 |
| 20 Analysts have issued a price target Novartis 2025 . The average Novartis target price is CHF102.52. This is 16.41% higher than the current stock price. The highest price target is CHF121.23 37.67% , the lowest is CHF82.17 6.69% . | |
| A rating was issued by 28 analysts: 6 Analysts recommend Novartis to buy, 19 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2025 of 16.41% . Most analysts recommend the Novartis stock at Hold. |
Sales and Margin forecast 2024, 2025 to 2028
21 Analysts have issued a sales forecast Novartis 2024 . The average Novartis sales estimate is CHF44.6b . This is 3.84% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF45.7b 6.60% , the lowest is CHF43.7b 1.90% .
This results in the following potential growth metrics:
Revenue Estimates
| 2023 | CHF40.8b | 1.30% |
|---|---|---|
| 2024 | CHF44.6b | 9.11% |
| 2025 | CHF46.4b | 4.06% |
| 2026 | CHF47.0b | 1.44% |
| 2027 | CHF48.3b | 2.70% |
| 2028 | CHF49.2b | 1.76% |
16 Analysts have issued an Novartis EBITDA forecast 2024. The average Novartis EBITDA estimate is CHF17.6b . This is 2.30% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF19.1b 5.97% , the lowest is CHF16.3b 9.41% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2023 | CHF18.1b | 11.03% |
|---|---|---|
| 2024 | CHF17.6b | 2.75% |
| 2025 | CHF18.9b | 7.20% |
| 2026 | CHF19.3b | 2.39% |
| 2027 | CHF20.8b | 7.64% |
| 2028 | CHF21.4b | 2.82% |
EBITDA Margin
| 2023 | 44.33% | 9.60% |
|---|---|---|
| 2024 | 39.51% | 10.87% |
| 2025 | 40.71% | 3.04% |
| 2026 | 41.09% | 0.93% |
| 2027 | 43.06% | 4.79% |
| 2028 | 43.51% | 1.05% |
15 Novartis Analysts have issued a net profit forecast 2024. The average Novartis net profit estimate is CHF9.9b . This is 35.07% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF10.9b 28.59% , the lowest is CHF9.1b 40.55% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2023 | CHF12.9b | 110.82% |
|---|---|---|
| 2024 | CHF9.9b | 22.85% |
| 2025 | CHF11.4b | 14.47% |
| 2026 | CHF11.9b | 4.67% |
| 2027 | CHF12.3b | 3.55% |
| 2028 | CHF14.0b | 13.87% |
Net Margin
| 2023 | 31.48% | 108.11% |
|---|---|---|
| 2024 | 22.26% | 29.29% |
| 2025 | 24.49% | 10.02% |
| 2026 | 25.27% | 3.18% |
| 2027 | 25.48% | 0.83% |
| 2028 | 28.51% | 11.89% |
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
15 Analysts have issued a Novartis forecast for earnings per share. The average Novartis <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is CHF4.96 . This is 35.08% lower than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is CHF5.46 28.53% , the lowest is CHF4.54 40.58% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2023 | CHF6.43 | 110.82% |
|---|---|---|
| 2024 | CHF4.96 | 22.86% |
| 2025 | CHF5.68 | 14.52% |
| 2026 | CHF5.94 | 4.58% |
| 2027 | CHF6.15 | 3.54% |
| 2028 | CHF7.01 | 13.98% |
P/E ratio
| Current | 11.53 | 61.19% |
|---|---|---|
| 2024 | 17.75 | 53.95% |
| 2025 | 15.51 | 12.62% |
| 2026 | 14.82 | 4.45% |
| 2027 | 14.31 | 3.44% |
| 2028 | 12.57 | 12.16% |
Based on analysts' sales estimates for 2024, the Novartis stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.21 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.87 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.37 | 4.38% |
|---|---|---|
| 2024 | 4.21 | 3.60% |
| 2025 | 4.05 | 3.90% |
| 2026 | 3.99 | 1.42% |
| 2027 | 3.89 | 2.63% |
| 2028 | 3.82 | 1.73% |
P/S ratio
| Current | 4.02 | 7.12% |
|---|---|---|
| 2024 | 3.87 | 3.70% |
| 2025 | 3.72 | 3.90% |
| 2026 | 3.66 | 1.42% |
| 2027 | 3.57 | 2.63% |
| 2028 | 3.51 | 1.74% |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
